Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor

这项试验是少数专门专注于将抗CD19 CAR T细胞应用于异基因移植环境的CAR试验之一。这项试验意义重大，因为与大多数抗CD19嵌合抗原受体试验不同，它不包括化疗，因此它对抗CD19 CAR T细胞的活性进行了纯粹的评估。我们继续为这项试验招募更多的患者。我们已经获得了有关每个患者的毒性和成功治疗的预测因素的重要信息。报道这场审判的论文(Brudno等人)发表在2016年的《临床肿瘤学杂志》上。该项目现在专注于测试用抗CD19 CAR转导的称为干细胞记忆T细胞(Ttscm)的分化较少的T细胞。在这项工作中，我们目前正在与另一位研究人员Luca Gattinoni合作，开发一种应用同种异体抗CD19汽车干细胞记忆T细胞的方法。在这项临床试验中，我们已经治疗了11例抗CD19 CAR TSCM细胞。1例急性淋巴细胞性白血病患者，在持续输注Tscm抗CD19 CAR T细胞后获得完全缓解。另一名淋巴瘤患者获得了部分缓解。这项试验现在已经结束了招募，报告结果的手稿正在准备中。许多相关的免疫学实验正在进行中。

This trial is one of few CAR trials exclusively focused on applying anti-CD19 CAR T cells to the allogeneic transplantation setting. This trial is significant because unlike most trials of anti-CD19 chimeric antigen receptors, it does not include chemotherapy, so it gives a pure assessment of the activity of the anti-CD19 CAR T cells. We continue recruit more patients for this trial. We have obtained important information on toxicity and predictors of successful therapy with each patient. A paper covering this trial (Brudno et al.) was published in the Journal of Clinical Oncology in 2016. The project is now focused on testing less-differentiated T cells called stem memory T cells (Ttscm) transduced with an anti-CD19 CAR. In this effort, we are currently collaborating with another Investigator, Luca Gattinoni, in developing a process for administering allogeneic anti-CD19 CAR stem memory T cells. We have treated 11 patients with anti-CD19 CAR Tscm cells on this clinical trial. A patient, with acute lymphoid leukemia, obtained a complete remission after infusion of Tscm anti-CD19 CAR T cells that is ongoing. Another patient with lymphoma obtained a partial remission. This trial has now ended enrollment and a manuscript reporting the results is in preparation. Many correlative immunology experiments are in progress.